Cargando…
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
BACKGROUND: PD-L1 is one of the major immune checkpoints which limits the effectiveness of antitumor immunity. Blockade of PD-L1/PD-1 has been a major improvement in the treatment of certain cancers, however, the response rate to checkpoint blockade remains low suggesting a need for new therapies. M...
Autores principales: | Munoz, Luis Enrique, Huang, Lei, Bommireddy, Ramireddy, Sharma, Richa, Monterroza, Lenore, Guin, Rohini N., Samaranayake, Sarah G., Pack, Christopher D., Ramachandiran, Sampath, Reddy, Shaker J.C., Shanmugam, Mala, Selvaraj, Periasamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611422/ https://www.ncbi.nlm.nih.gov/pubmed/34815353 http://dx.doi.org/10.1136/jitc-2021-002614 |
Ejemplares similares
-
Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models
por: Munoz, Luis E., et al.
Publicado: (2021) -
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
por: Yu, Xiaolu, et al.
Publicado: (2022) -
Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020) -
Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Taki, Shunichi, et al.
Publicado: (2021) -
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
por: Khalique, Hena, et al.
Publicado: (2021)